RISK OF ADVERSE GASTROINTESTINAL OUTCOMES – (01-09-06)



Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

Isn’t this just the biggest kick in the gluts? A new class of drugs, the selective COX-2 inhibitors like Vioxx and Celebrex are born and a market created by clever marketing campaigns to let people know that the “other” anti inflammatories can damage the GI tract. These drugs get handed out like candy, nearly bankrupting healthcare in some countries due to their high cost. Soon the evil side is seen in an increased tendency to clot the blood, leaving tens of thousands dead. Here’s the kicker—it may turn out that this class of drugs is not so good at doing what it was supposed to do better!! Run that by the widows and orphans whose loved ones suffered untimely deaths.

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Drug Research
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”